Wellness & Lifestyle

egnite Health offers the CardioCare platform, a digital health solution that utilizes artificial intelligence-driven algorithms to generate business intelligence for healthcare. The platform is designed to identify and improve outcomes for cardiovascular patients in the U.S. by analyzing large datasets. CardioCare supports progressive cardiovascular centers with solutions across valve disease, heart failure, and atrial fibrillation, and also aids in clinical trials. For life sciences, egnite provides the Therapy Accelerator & Research, offering access to one of the largest ecosystems of real-world cardiovascular data. The platform aims to enhance human intelligence with AI to guide critical decisions in healthcare, ultimately advancing the cardiovascular health of society.

Fabric Genomics, now part of GeneDx, offers AI-powered software and clinical services designed to transform genomic data into actionable clinical insights. The platform supports rapid and accurate diagnostics for applications such as hereditary risk screening, rare disease diagnosis, and rapid NICU testing. By leveraging explainable AI, Fabric Genomics automates workflows, provides accurate results quickly, and generates physician-ready clinical reports. Its cloud-based software is scalable, capable of handling everything from a single test to hundreds of thousands, making it a solution of choice for leading genomics programs worldwide.

insitro is a pioneering drug company that integrates machine learning (ML) and large-scale data to revolutionize drug discovery and development. By decoding the complexities of biology, insitro aims to bring better drugs faster to patients. The platform combines in vitro cellular data from its labs with human clinical data to redefine disease understanding. This ML-driven approach is engineered to precisely identify therapeutic insights and interventions across a wide spectrum of diseases, accelerating the development of new medicines. insitro is building a pipeline of wholly-owned and partnered therapeutic programs in key areas like metabolism, oncology, and neuroscience, all fueled by its robust data-driven platform.

Revilico is an AI-powered platform designed to digitize and accelerate pharmaceutical research and development. It provides a comprehensive ecosystem for drug discovery, empowering chemists and biologists with unified virtual simulations, AI models, and closed-loop experimentation. The platform integrates core engines like Docking, Co-folding, Molecular Dynamics, FEP+, Generative and Quantum Chemistry, and Virtual Cells to cover the entire drug discovery spectrum from Target ID to Preclinical Development. Revilico aims to reduce screening hit rates, experimental reduction efficiency, and lead generation costs, ultimately enabling faster and more precise development of new medicines. It also features a robust data ecosystem, harmonizing vast amounts of biomedical data to bridge the gap between computational and experimental scientists.

Qlucore provides visualization-based solutions to accelerate, simplify, and improve research and cancer diagnostics. The platform offers powerful, flexible, and easy-to-use tools for multi-omics data analysis, including bulk RNA-seq and proteomics. It integrates publicly available resources and supports a broad spectrum of omics data types like RNA-seq, NGS, proteomics, and metabolomics. Key features include real-time 2D and 3D interactive plots, powerful statistical analysis with instant visualization, and a Biomarker Workbench optimized for drug development and biomarker discovery. Qlucore also supports machine learning classifiers and offers an NGS Module for genome browser-centric analysis, including fusion gene analysis and single-cell RNA-seq data support. It is available in both cloud and local installations.

OKRA.ai, integrated within Envision Pharma Group, is an AI and technology solution designed for the life sciences sector. It combines AI-powered technology with medical, commercial, and strategic expertise to help organizations achieve smarter, faster outcomes and real-world impact for patients. The tool supports various functions across the product lifecycle, including evidence generation, medical affairs, commercialization, market access, revenue management, and compliance. It aims to accelerate access to life-changing treatments by providing integrated and scalable solutions, enabling better decisions, stronger governance, reduced risk, and accelerated impact for clients.

Weave Bio is an AI-native regulatory platform designed to transform how biotech and pharma teams prepare and manage complex dossiers throughout the therapeutic life cycle. It automates regulatory submissions, IND filings, and HAQ management, speeding up data organization, authoring, review, publishing, and response management. The platform provides eCTD-formatted templates and AI-driven content generation for documents, tables, and figures, ensuring fast, accurate, and confident submissions. Weave Bio emphasizes expert-led AI, allowing users to direct the AI to solve problems and shape narratives. It also offers real-time collaboration features, including commenting, version tracking, and data verification, and a connected system for managing therapeutic development across all stages and modalities.

Biomod AI acts as an AI-powered bioinformatician, offering on-demand expertise for molecular biology workflows. It handles tasks from in silico design to complex data analysis, including primer design, sequence analysis, gene expression, CRISPR design, and NGS pipelines. Users describe their analysis needs in plain language, and the AI processes the request using validated pipelines, with expert review ensuring accuracy. The tool delivers publication-ready reports, data tables, and visualizations, not just raw terminal output. It integrates with over 1,000 tools and databases like BLAST, Primer3, NCBI, and UniProt, providing comprehensive support for life science research without the need for in-house bioinformatics hires.

Growdea Technologies Pvt Ltd is an AI-driven life sciences company dedicated to advancing drug discovery through cutting-edge computational biology. Their platforms leverage in-silico intelligence and machine learning to accelerate pharmaceutical innovation. By integrating data, machine learning, and physics-based rules, Growdea Technologies aims to streamline the drug development process. Their expertise includes predicting drug efficacy and toxicity, developing in-silico vaccines, and optimizing clinical trial designs. The company focuses on providing scalable solutions for faster and more efficient research in the pharmaceutical sector.

Caris Life Sciences is a leading TechBio company dedicated to transforming cancer care through precision oncology. They provide advanced laboratory testing, such as comprehensive tumor profiling and blood-based cancer diagnostics, to inform personalized treatment options. By combining massive amounts of genomic, transcriptomic, and proteomic data with clinical outcomes, Caris has built one of the world's largest multimodal databases. This enables them to apply sophisticated AI bioinformatics and machine learning to classify cancer at the molecular level and predict patient response. Their services support the full continuum of care, from disease detection and therapy selection to treatment monitoring, empowering patients, physicians, and biopharma partners with critical molecular insights.

Chemdelve Private Limited, initially founded as a contract research organization in chemistry, has expanded its services to include artificial intelligence and robotics. The company offers comprehensive digital transformation solutions, encompassing AI & Data Analytics, Optimization and Modelling, Connected Workers (Mobility), Inferential Analyzers and Soft Sensors, Virtual Reality (VR) & Augmented Reality (AR), Smart and IoT Devices, Blockchain, Cybersecurity, Robotic Process Automation, and Robotics and Drones. They cater to various industries such as Oil and Gas, Chemicals, Manufacturing, Electrical & Renewable Utilities, Water & Waste Water Utility, Mineral Resources, and Life Sciences and Material Chemistry. Chemdelve also provides chemistry consultancy services and collaborates with Artificial Intelligence Global Company (AIGC) for AI and digital transformation services.

Chai Discovery is at the forefront of biochemical innovation, leveraging advanced artificial intelligence to predict and reprogram the intricate interactions between biochemical molecules. The platform is dedicated to building frontier AI solutions for critical biochemical applications, particularly in drug discovery. A key focus is on engineering superior molecules, including drug-like antibody design with atomic precision. With its Chai-2 technology, Chai Discovery aims to move de novo antibody design beyond simple binding, bringing it closer to the development of real therapeutic solutions. This advancement is crucial for tackling challenging targets in pharmaceutical research and development.

Alysophil is an innovative platform that merges continuous flow chemistry with artificial intelligence to establish a foundation for a sustainable chemical industry. The tool addresses the paradoxes in modern chemistry, such as the demand for more products alongside a growing aversion to risks, and the need for cheaper yet greener production methods. Alysophil aims to accelerate the chemical industry's evolution by offering services that are safe, frugal, agile, and intelligent. It leverages AI to generate novel molecules and optimize industrial projects, contributing to more efficient and environmentally friendly chemical manufacturing processes. The platform's approach helps industrial partners meet current challenges and achieve optimal holistic performance.

CluePoints provides Risk-Based Quality Management (RBQM) software solutions specifically designed for clinical trials. Leveraging advanced statistics and machine learning, the platform illuminates real-time data anomalies and potential risks that could compromise patient safety or data integrity. Key features include RBQM Detection, Documentation, and Services, along with specialized tools like the Site Profile & Oversight Tool (SPOT) for adaptive site monitoring, Intelligent Medical Coding for automated coding suggestions, Medical Safety Review (MSR) for periodic data review, and Intelligent Query Detection (IQD) for automating data discrepancy detection. CluePoints aims to revolutionize clinical trials by providing best-in-class integrated data review, empowering clients to achieve positive outcomes in clinical development.

PEACCEL is an AI company specializing in Life Sciences, offering an end-to-end solution for drug discovery, from the initial 'hit to lead' phase through to preclinical trials. The platform leverages dedicated AI tools to identify promising drug targets and optimize enzymes or bioreactors for higher yields. PEACCEL focuses on capturing the synergistic effects of mutations to find drug lead candidates and screens billions of mutants daily using its innov'SAR AI platform. By generating synthetic data to train its machine learning models, PEACCEL aims to significantly improve hit rates in drug discovery and reduce the risks associated with patent loopholes, supporting strategic partnerships with key players in the chemical, biotech, and pharma industries.

Synlico Inc. is at the forefront of AI-driven drug discovery, integrating artificial intelligence, single-cell bioinformatics, and causal cell modeling to develop potent therapies. The company's mission is to revolutionize biology by making cellular processes quantitatively explainable, predictable, and engineerable through causality. Synlico specializes in identifying causal links between intracellular activities and patient responses, predicting how cell modulation alters behavior in patients. Their computational platform addresses key problems in drug design, such as the disconnection with disease microenvironment heterogeneity and the discrepancy between in-vitro/animal results and patient responses, by focusing on targeted drug design and predicting causal effects of gene interventions.

Qureator provides an advanced platform that integrates human disease models with an AI engine to evaluate treatment efficacy in complex disease models. Utilizing CurioChip technology, it recreates human biology with patient-derived cells, enabling high-throughput testing of small molecules, biologics, cell & gene therapies, and CRISPRi. The QuriCore AI platform supports new target identification, discovery of synergistic combinations, and prediction of efficacy and dosage. This technology is applied across various disease models including cancer metastasis, age-related macular degeneration (AMD), and drug-induced liver injury (DILI), aiming to improve drug discovery and development by testing treatments with human tissue before human bodies.

DeepPurpose is a comprehensive deep learning toolkit designed for molecular modeling and prediction in life science research. It supports various applications including Drug-Target Interaction (DTI) prediction, Compound Property Prediction, Protein-Protein Interaction (PPI) prediction, Drug-Drug Interaction (DDI) prediction, and Protein Function prediction. Built on PyTorch, DeepPurpose offers over 15 powerful encodings for drugs and proteins, ranging from cheminformatics fingerprints to graph neural networks, providing over 50 combined models. The library is designed for realistic and user-friendly applications, supporting tasks like drug repurposing, virtual screening, QSAR, and side effect prediction. It includes features like automatic task identification (regression/binary), support for cold target/drug settings, extensive dataset loading scripts, pretrained checkpoints, and detailed training metrics with early stopping. DeepPurpose is actively maintained and encourages user feedback.

ArcaScience is an AI-powered platform designed for pharmaceutical companies to streamline benefit-risk assessments throughout the entire drug lifecycle, from preclinical framing to post-marketing surveillance. The platform leverages 24 proprietary AI models and over 100 billion data points to provide complete visibility and accelerate regulatory decisions. It automates critical processes like comparative assessment, evidence scoring, and the generation of submission-ready documents such as PSURs, RMPs, and CTD 2.5 B-R sections. ArcaScience helps reduce manual analysis time, synthesize fragmented data, and mitigate high failure costs associated with drug development, ensuring compliance with FDA 21 CFR Part 11, GDPR, and ISO 27001.

Cresset offers digital molecular discovery solutions powered by science and enriched by AI, aimed at accelerating drug discovery. Their tools, such as Flare™, Spark™, and Blaze™, assist computational and medicinal chemists in generating smarter ideas, making stronger decisions, and designing better molecules. The platform streamlines the discovery process from target validation to candidate selection, offering capabilities like ligand and structure-based design, scaffold hopping, bioisosteric replacement, and AI-powered ADME model building. Cresset also provides discovery services and boasts robust science with features like Active Learning FEP to accelerate lead optimization, demonstrating increased success rates. Their solutions are trusted by the scientific community and are designed to enhance productivity in chemistry workflows.

OmniumAI is an AI and data science company specializing in bioinformatics and chemoinformatics. It offers consulting, software development, and training services, primarily assisting biotechnological companies with complex data analysis, mining, and integration challenges. The platform aims to decode life and leverage natural processes using advanced machine learning techniques, providing solutions for scientific research and development. Its focus on these specialized fields makes it a valuable resource for organizations looking to apply AI to biological and chemical data.

NTv3 is an AI-powered tool that provides foundation models specifically designed for long-range genomics research. Hosted on Hugging Face, it offers a convenient hub for users to access ready-to-run PyTorch notebooks. These notebooks facilitate various genomic tasks, including inference, fine-tuning, interpretation, and sequence generation. Researchers can input DNA/RNA sequences or training data to leverage the models' capabilities for advanced genomic analysis. The platform is developed by InstaDeepAI, making cutting-edge AI models accessible for scientific computing in the genomics domain.

Chemical.AI offers the ChemAIRS platform, an AI-driven solution for advancing retrosynthesis and molecule synthesis. It goes beyond traditional retrosynthetic analysis by incorporating features like synthesizability assessment, process chemistry insights, impurity prediction, and forward synthesis. The platform utilizes advanced AI and expert rules to generate feasible and diverse synthetic routes, helping chemists optimize yield, reduce costs, and shorten synthesis times. ChemAIRS integrates millions of building block data points and ELN entries to enhance reliability and efficiency, empowering users to confidently plan chemistry synthesis projects and accelerate the development of novel compounds.

Tierra Biosciences, operating under the name Revr, is an AI-driven protein discovery engine designed to revolutionize protein-based therapeutics. The platform focuses on high-performance protein design, offering rapid development, optimization, and synthesis capabilities. By leveraging artificial intelligence, Revr aims to eliminate the guesswork traditionally associated with protein engineering, providing a more efficient and grounded approach to biological reality. This tool is geared towards accelerating the discovery and development of protein-based solutions, making it a valuable asset for professionals in the biotechnology and pharmaceutical sectors.